NCT03963973View on ClinicalTrials.gov

A 28 Day Parallel Group Study to Assess the Effects of RDN-929

PHASE1TerminatedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

May 16, 2019

Primary Completion Date

January 22, 2020

Study Completion Date

January 22, 2020

Conditions
Healthy
Interventions
DRUG

RDN-929 oral capsule

low, medium and high dose

DRUG

Placebo oral capsule

matching placebo dose

Trial Locations (2)

Unknown

Brain Research Center, Amsterdam

QPS Netherlands B.V., Leeuwarden

Sponsors

Lead Sponsor

Alkermes, Inc.
All Listed Sponsors
lead

Alkermes, Inc.

INDUSTRY